.... The predecessor of the company is a Sino-foreign joint venture invested by Abbott International Limited (ABBOTT). The company introduced the advanced technology and management experience of ABBOTT. The production equipment and production conditions are of international first-class standard, and the company is the first professional enterprise in China that produces and sells internationally advanced biochemical reagents and pharmaceutical preparations. In order to better adapt to the needs of the development of high-tech products and to meet the challenges of international economic integration, the company invested another 70 million yuan in 2002 in the hardware design and construction and the introduction of technology, product development and other aspects of the strategic adjustment of the product structure, increasing the proportion of proprietary Chinese medicines and new reagents. The company has built a new plant in the joint development zone in line with GMP requirements, the production line adopts German and Italian imported equipment. The main production equipments are liquid phase test qi preparation and filling line, packaging. Drug tablets and capsules assembly line, QC laboratory with advanced testing methods.
.... Asia-Pacific company in China's pharmaceutical industry, especially in the field of clinical diagnostic reagents production and marketing has a strong strength and high visibility. With dozens of professional and technical personnel engaged in the development of the national market and sales management, product after-sales service is becoming more and more perfect. At present, the company has set up specialized sales and service organizations in 20 large and medium-sized cities across the country, and has good business relations with international famous authoritative companies such as Landau of the United Kingdom, Medical Jie of France and Wako of Japan.
The company adheres to the business philosophy of survival by quality, development by science and technology, and benefit by management, and actively develops and develops high-tech and high value-added pharmaceutical products and clinical diagnostic reagents. The products are sold in more than 20 provinces, autonomous regions and municipalities directly under the central government, and are trusted and praised by the majority of patients.
.... The company has been awarded AAA grade credit enterprise by Ningbo Credit Evaluation Committee, Jinhui International Consulting and Development Company and Agricultural Bank of China Ningbo Branch for consecutive years. It is a member of China Association for the Promotion of International Trade and China International Chamber of Commerce.
.... In the introduction of technology, product development: the company and China Pharmaceutical University signed a "comprehensive technical cooperation framework agreement", and with the Pharmaceutical University of Chinese medicine compound research laboratory cooperation *** built "Ningbo joint Chinese medicine and compound modernization and development laboratory". In addition, the company has invested nearly 30 million yuan in the development of new drug varieties. At present, we are cooperating with the University of Pharmaceutical Sciences*** on the research of 95 research projects, the third category of new drugs in traditional Chinese medicine, "Xinde Kang Granules", and from 2001 onwards, we will*** develop a second category of new drugs and a third category of new drugs every year.
.... At the same time, the company also with Zhejiang University, Shanghai Medical Industry Research Institute, China Pharmaceutical University International Pharmaceutical Business School and other high-level scientific research colleges, teaching institutions *** together, relying on their technology and knowledge, the development of high-tech products, market planning and development, and strive to build the company into a world-renowned domestic and international pharmaceutical enterprises.